We cordially invite you to the 3rd World Biomarkers Summit to be held at Rome, Italy on April 22-23, 2020. The 2020 edition of the Biomarkers conference will move forward with the theme “Biomarker as a future protagonist ”. Biomarkers 2020 concentrates on procuring emerging researches in the sector of medicine and health brought to us via applications of biomarkers. Scientists, Young researchers, pharmaceutical industrialists and medical professionals are expected to form a global networking through this conference thereby getting and letting explore the topic to a greater extent. This meeting deals with field of immunology, nutrition, epidemiology, cancer biology, targeted cancer therapies and cancer pharmacology, etc. Rome has been finalized as the venue for the summit and is full of tourists’ attraction places. We welcome participants from all over the globe to join us for the summit as well as to explore the beautiful city.
Session on: Biomarkers
Biomarkers, in other words, biological markers deal with medical science being a source of identification and observation of varied underlying diseases. Observable signs are sometimes in contrast to medical symptoms, which are limited to those indications of health or illness perceived by patients themselves. They allow the assessment of such symptoms via a therapeutic interference thereby framing a pharmacological response. This session of Biomarkers 2020 includes the basic ideology behind heterogeneous biomarkers relating to their discovery, validation, and verification.
Session on: Prognosis, Diagnosis and Prediction
Classification of biological markers is broadly divided into three categories i.e., Prognostic, Diagnostic and Predictive basing upon their functionality and implementation methodology. As the names suggest some are being put to use before initiating the treatment while others act as indicators after implementation of medical procedure. Biomarkers linking to early indication of certain risk factors help in curbing the diseases prior to any severe damage. Biomarkers 2020 intends to gather people from varied sectors to provide us with the knowledge of types of biomarkers and their proper uses.
Session on: Lifestyle and Medication
Lifestyle of people i.e., nutrition, medication, nursing in specific is being critically enhanced by the application of biomarkers. Pathogens such as viruses, bacteria, parasites, or fungi causing infectious diseases have been a major threat around the globe and have a huge impact on public health and the world economy. Diseases linked to our metabolism like diabetes, respiratory chronic diseases and cardiovascular diseases are much predominant on today’s date. Session on this topic links to cancer, nutrition, nursing and alternative medicine, metabolomics-based investigations and non-cancerous diseases as well.
Session on: Cancer Therapies and Therapeutics
Oncology is linked to the usage of biomarkers for determination of a patient’s risk of developing a malignancy using risk reduction strategies (such as lifestyle changes, prophylactic surgery, or chemoprevention). Biomarkers have been proven to be a certified indicator of such malignancies at the initial stages. These can be used for patient assessment of patients including estimating risk of disease, screening occult primary cancers, distinguishing benign from malignant impressions or one type of malignant finding from another, prognosis and prediction for patients diagnosed with cancer, and surveillance of the disease, either to detect iterating factors or response to therapy. Biomarkers bring the department of Oncology and the sectors related such as cytological biomarkers, biomarkers for cancer stem cells, haematological cancer, etc.
Session on: Immuno-Oncology
Immuno-oncology focuses on working and preaching assistance from our own immune system so as to opt for treatments to fight cancer. Cancer-targeting immunotherapy works with the perspective of modeling the immune system in a way through which it perceives cancer as a foreign entity and starts prepping up to curb it at its initial stage.This session links to various general immunotherapies, cancer linked immunotherapies (monoclonal antibodies, etc.), immunotherapies linked with other treatments like radiology, chemotherapy, surgery.
Session on: Molecular Genetics
Genetic mutations nowadays are a source of biomarkers and are widely in use. Molecular markers and translational markers play the kingpin in certain genre of cancers e.g. lungs cancer, hepatic cancer, etc. in determining and mitigating the same. The coincidence of genetic toxicity events with the initial stages of cancer has aggravated great interest in molecular/cytogenetic epidemiological studies for implementing DNA repair along with carcinogen metabolism and DNA biomarkers with cancer risk. Talks and ideologies in this session could provide information regarding cytological epidemiology, DNA markers, epigenetic mediated gene silencing, and translational diagnosis.
Session on: Drug Development
Drug discovery and drug development coupled with biomarkers are used exclusively for the diagnosis and monitoring of patients in clinical trials. Biomarkers enhance the success rate of drug development programmes and thereby accelerate the availability of advanced therapeutics. Biomarker development is a multistep and recurrent process starting with biomarker discovery in infectious diseases. In this session, analytical validation phase of biomarker development, pharmacogenomics, functional proteomics, bio analytical method of validation, pharmacokinetic and pharmacodynamics models.
Session on: Nanotechnology for Biomarkers
Nanoparticle-based assays are gradually unfolding as an upcoming approach, providing ultra-high sensitive and specific detection in case of cancer biomarker. The on-going survey presents an overview of methodologies used in the development and usage of nanoparticles for the detection of cancer biomarkers including mass spectrometry, optical and electrical detection methods. Nanoparticles are highly sensitive, selective and accelerate biomarker detection methods, emphasising their detection probabilities in assays for trace amounts of a biomarker in various types of biological ï¬‚uids be it tears or urine.
Session on: Emerging Therapeutic Biomarkers
Therapeutic Biomarkers are emerging to newer heights along with improvised advancements in their way of operation. This is generally a protein that could be used as target for a therapy. Most of the emerging biomarkers hail from the diagnosis and prognosis related to cancer and tumor therapies. This session of Biomarkers 2020 deals with Biomarkers as surrogate endpoint for clinical trials, Biomarkers for targeted therapy, immuno-oncology.
Session on: Clinical Research & Biomarkers
Clinical research governs the productivity and safety of various products and inventions proposed for human use. In this process the validity, shelf life, threats and efficacy of the biomarkers in various fields is being tested and verified. This session includes the usage of biomarkers (especially pharmacodynamics) for biomarkers in sectors of oncology, immunology, neurology, epidemiology.
Session on: Biomarker Testing
Biomarker testing performs tests that focuses on the molecular signs of health so that there will be proper diagnosis and care. Certain tissues or fluid samples are being collected for the experimentation thereby providing a prognostic idea about any alarming threat to health. This section plays a key role in the Biomarker 2020 as it includes the ethical issues, process of implementation, experimentation and organised observation of biological markers for the diagnosis purpose.
Session on: Advances and Future Perspective
Biomarkers are considered as the lynchpin of future medicine in regards to their advancement and accuracy. Investors and industrialists especially in the sector of pharmaceuticals and epidemiology are booming at an alarming rate because of the profits and high revenue. In the sector of medicine the contribution of biomarkers still remains unmatchable. This session anchors all the future perspective of biomarkers, advancements and applications as well.
The basis of Biomarkers 2020 is to gather eminent personalities and professionals from the sectors of pharmacy, medicine and research sharing similar interests and ideologies regarding prevalent diseases especially in the department of oncology and the ways of mitigations linked. Biomarkers 2020 purposes to bring forth the information regarding new line tech savvy methodologies used in Biomarkers with the applications from nanotech for curbing nightmarish diseases like cancer.
Why to attend Biomarkers 2020?
3rd World Biomarkers Summit invites renowned and experienced personnel hailing from fields like Oncology, Neurology, Epidemiology, Immunology, Nanotechnology, Nutrition, Medicine, Pharmaceuticals. The Conference will be composed of many exciting academic programs including multiple panels, workshops, affinity group lunches, paper presentations, and scientific sessions by professionals. Nonetheless everyone who will be a part of this gets certification for their participation, personal brand establishment and rebuild customer base.
We plan to provide all delegates and high skilled professors with all possible basic amenities and for attendees a source of knowledge regarding all the imminent technologies lined up.
Importance and Scope:
Theme of the conference “Biomarkers As A Future Protagonist” conveys the basic notion we are willing to showcase to the world. Biomarkers 2020 prioritizes the high end technologies used for human welfare and convenience. People from every genre i.e. the highly classified professionals, budding industrialists and young innovators have a great deal in this as they will be having a chance for diversification and global communication. We believe Biomarkers 2020 will come out as an academic exploration and a platform full of public awareness.
Business Value of Biomarkers:
Major market players include Abbott Laboratories, Medtronic, BG Medicine Inc., Hoffmann LA Roche Ltd., Siemens Healthnineers, Nexus-DX, Qiagen N.V., Lifesign LLC
List of universities associated with Biomarkers in Worldwide:
- United Arab Emirates University, UAE
- The University Of Arizona, US
- University of Leicester, UK
- University of Skövde, Sweden
- Technical University of Munich, Germany
- University of Modena and Reggio Emilia, Modena, Italy
List of universities associated with Biomarkers in Italy:
- University of Bergen
- University of Catania
- University of Pisa
- University of Florence
- University of Perugia
- European Institute of Oncology
- University of Cagliari
List of Research centres Worldwide:
- Centre for Individualized Medicine, USA
- CBmed, Austria
- Research Centre on Computational Biomarkers, Germany
- Centre for Biomarker Discovery & Translation, USA
- Manchester Biomedical Research Centre, England
- Allergy and Clinical Immunology Research Group, Belgium
List of Research centres in Italy :
- Centre for Cancer Biomarkers CCBIO
List of Hospitals Worldwide:
- Children’s Hospital of Philadelphia, USA
- Hospital Healthcare Europe
- St. Jude Children’s Research Hospital, USA
- UK National Health Service
List of Hospitals in Italy:
- Charles University and Thomayer Hospital, Prague, Czech Republic.
- Gazi University School of Medicine, Ankara, Turkey.
- Athens Chest Hospital, Athens, Greece
- Erasmus Medical Center, Rotterdam, the Netherland
- Bambino Gesù Children's Hospital, Rome
- Asthma and Allergy - Humanitas Research Hospital, Milan
- San Raffaele Hospital, Milan
- Santa Corona Hospital , Savona
- University Hospital, Ferrara
- Ramazzini Hospital, Carpi
- S. Anna University Hospital, Ferrara
- S. G. Moscati Hospital, Avellino
Funding on biomarkers:
Biomarkers Market worth $40.8 Billion by 2018
Forecast for next 5 years:
Biomarkers are successfully predicting drug efficacy hastily than conventional clinical endpoints. These aids of Biomarker will also be swelling its demand among the end-user industries over the upcoming years. Sectors from oncology to medicine to nanotech, Biomarkers have been spreading its branches all along within these years and plans to have more expansion of territory in the field of science and technology in the future.
Biomarkers hold a latent position for the world of medicine and healthcare. This is the era of technology and every day is a day of new innovation and invention. Expertise increases day by day so as our expectations and lifestyle. We can hope for better tomorrow where we observe early detection possibly not only for cancer but for other diseases also.